ViroGates A/S
CSE:VIRO
Gross Margin
ViroGates A/S
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | Company | Market Cap |
Gross Margin |
||
---|---|---|---|---|---|
DK |
V
|
ViroGates A/S
CSE:VIRO
|
75.5m DKK |
45%
|
|
US |
![]() |
Abbott Laboratories
NYSE:ABT
|
230.4B USD |
56%
|
|
US |
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
168B USD |
67%
|
|
US |
![]() |
Boston Scientific Corp
NYSE:BSX
|
155.4B USD |
68%
|
|
US |
![]() |
Stryker Corp
NYSE:SYK
|
147.5B USD |
65%
|
|
IE |
![]() |
Medtronic PLC
NYSE:MDT
|
118.1B USD |
65%
|
|
DE |
![]() |
Siemens Healthineers AG
XETRA:SHL
|
53.5B EUR |
39%
|
|
US |
![]() |
Becton Dickinson and Co
NYSE:BDX
|
56.9B USD |
45%
|
|
US |
![]() |
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.1B USD |
62%
|
|
US |
![]() |
Edwards Lifesciences Corp
NYSE:EW
|
47.9B USD |
79%
|
|
US |
![]() |
Resmed Inc
NYSE:RMD
|
42.2B USD |
59%
|
ViroGates A/S
Glance View
ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on ViroGates A/S's most recent financial statements, the company has Gross Margin of 45.5%.